Furthermore, we showed that the combination of PS and biological covariates such as LDH, lymphocyte and platelet counts, serum albumin and IL-6 levels is an effective strategy to predict survival for patients with advanced or metastatic cancer receiving further treatment after the first-line. The gene discussed is IL6; the disease is metastatic malignant neoplasm.